Global stock

SIXCHF

Roche Holding AG

ROG.SW

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

67/ 100

Overall score·ROG.SW

Current price

397.4CHF

23/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Forward P/E 17,4 a EV/EBITDA 13,9 naznačují přiměřenou valuaci, zatímco P/B 9,4 a PEG 1,76 ji při současném poklesu EPS činí méně atraktivní. Nejsilnějšími stránkami jsou ziskovost, stabilita a růstový cenový trend; slabší je aktuální vývoj tržeb a zisků.

§ Outlook vs S&P 500Next 12 months

Probably yes

Estimated chance of beating the index: about 55%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at Roche Holding AG (ROG.SW) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

67/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

60/100

Slightly positive signal based on current news, price action and the economy.

50/100

A lower score means the stock is expensive relative to the company's earnings and assets.

16% above fair value

An estimate of what the stock should be worth based on the company's future cash.

-1%

How fast the company's revenue grows year on year.

85/100

How much the company earns from each unit of revenue and from invested capital.

82/100

Debt level, share-price volatility and how resilient the company is in bad times.

76/100

AI estimate of management quality, execution and capital allocation.

88/100

AI estimate of the company's durable competitive advantage.

§ Financial results

Financial results·ROG.SW

mld. CHF

RevenueEBITDANet incomeEBITDA margin

Margins and profitability·ROG.SW

Net marginEBITDA marginDashed = estimate

Net margin

+20.9 %

FY 2025 · reported

EBITDA margin

+35.3 %

FY 2026 · estimate

Net margin

+19.6 %

last 12 months

Operating margin

+36.2 %

last 12 months

ROE

+38.1 %

last 12 months

FY = fiscal year · TTM = trailing 12 months

§ Context and events

Management

Výkonným předsedou představenstva je Severin Schwan, skupinu vede CEO Thomas Schinecker a finančním ředitelem je Alan Hippe. Wafaa Mamilli zastává funkci ředitelky pro digitální technologie. Strategie propojuje farmaceutický výzkum a diagnostiku a klade důraz na vývoj nových léčiv a digitální využití dat.

Articles about Roche Holding AG, in Czech (1)

Roche pokračuje s investicí v Německu navzdory vládním škrtem na zdravotnictví

Švýcarský farmaceutický gigant Roche potvrzuje pokračování v plánované investici 600 milionů eur do nové diagnostické výroby v Německu, přestože německá vláda navrhuje úsporná opatření ve zdravotnictví. Tento krok ukazuje na důvěru firmy v dlouhodobý růst a stabilitu německého trhu, který je klíčový pro její evropské aktivity.

9 June 2026· 3 min

§ Frequently asked questions

What is Roche Holding AG (ROG.SW)?

Roche Holding AG (ROG.SW) is a global stock traded on SIX. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Roche Holding AG price today?

As of 23 October 2026, Roche Holding AG trades at about 397.40 CHF per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Roche Holding AG?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Roche Holding AG pay a dividend?

Roche Holding AG either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Roche Holding AG a good investment in 2026?

Our AI signal currently rates Roche Holding AG as slightly positive (score 60/100). Financial health comes out at 67/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 16 % above its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

Amazon.com Inc.

AMZNhealth 68/100

§ How to buy Roche Holding AG

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

News summary

Older news

Signal 26/10, 07:01

Roche má podle zprávy zveřejnit výsledky zítra; pozitivní cenový trend by mohl pokračovat, pokud výsledky překonají očekávání, jinak může přijít korekce.

Cena za 7 i 30 dní roste a momentum je silné, což podporuje krátkodobý výhled. RSI 71 a vysoká volatilita ale zvyšují riziko výkyvu; dlouhodobý obraz zůstává vyvážený.

Risks: Slabší výsledky nebo výhled, případně pokles podpořený vybíráním zisků, by mohl růstový trend rychle zvrátit.

More about the signal

Cena za 7 i 30 dní roste a momentum je silné, což podporuje krátkodobý výhled. RSI 71 a vysoká volatilita ale zvyšují riziko výkyvu; dlouhodobý obraz zůstává vyvážený.

Risks: Slabší výsledky nebo výhled, případně pokles podpořený vybíráním zisků, by mohl růstový trend rychle zvrátit.

Signal history· 2

04/1018:0155 · Neutral
Roche zůstává v centru investorů kvůli vyrovnané trajektórii výsledků a makro podmínkám; žádné extrémní nové drive.
02/1015:3073 · Strongly positive
Roche čelí pozitivní trendové náladě díky rostoucímu segmentu biomarkerů a silné jměnově fundamentální perspektivě v segmentu diagnostiky.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Fairly valued16% above fair value

341.54

range 264.8 – 456.4

Current price

397.40 CHF

23 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

341.54 CHF

range 264.8 CHF – 456.4 CHF

: 5.0%
: 8.0%
: 16.43 CHF

Růst FCF 5 % p.a. je konzervativní předpoklad pro zavedenou farmaceutickou společnost a zohledňuje aktuální pokles tržeb i EPS. Diskontní sazba 8 % reflektuje stabilní charakter odvětví a nízkou betu; terminální růst 2,5 % je nižší než diskontní sazba.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 18 of 18

Valuation score

1/ 6

5/6 tests available

1. Below DCF fair value

16.4% above the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

99% above the 1-year low (300.9 CHF to 398.0 CHF), based on stored daily prices.

4. P/E vs. similar companies

P/E 25.0 vs. median 26.7 (71 companies).

5. P/E relative to growth

PEG 1.8; a lower value means cheaper growth.

6. Analyst price target

A price target exists, but coverage is too low to count in the score.

Price vs DCF

Current price

397.4 CHF

Low 264.8 CHFHigh 456.4 CHF

Current priceDCF midpoint: 341.5 CHF

Price vs analyst target

Current price

397.4 CHF

Low 340.0 CHFHigh 396.0 CHF

Current priceAverage: 368.0 CHF

DCF gap

within range

The price is within the model range of 264.8 CHF to 456.4 CHF.

Analyst target

-7.4%

Average target 368.0 CHF vs. price 397.4 CHF.

Analyst consensus

Target range

340.0 CHF - 396.0 CHF

Coverage

2 analysts

Analyst consensus

2.3 / 5

Changes 180 d

+0 / -0

EPS next year

8.1%

Revenue next year

4.7%

Valuation multiples

25.0

17.4

9.4

4.9

13.9

1.8

52-week range99% above the low

300.9 CHF398.0 CHF

-8.0%

-1.0%

19.6%

38.1%

Price vs 50D8.1%

Price vs 200D14.0%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 23/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

strong

Vedení má jasné zaměření na rozvoj pipeline, efektivitu a stabilní cash flow, avšak výsledky zatím doprovází pokles EPS a tržeb.

strong

Roche těží z rozsáhlého farmaceutického portfolia, diagnostické divize a výzkumných kapacit, které vytvářejí silné bariéry vstupu; patentová expirace a biosimilars však tuto výhodu oslabují.

Information

Type: Global stock
Symbol: ROG.SW
Exchange: SIX
Currency: CHF
Sector: Healthcare
: 25.0x
: 306.4B USD
: 90.7 %
: 0.33

§ Risk profile

Výsledky mohou oslabit neúspěšné klinické studie, cenový tlak na léčiva nebo ztráta patentové ochrany. Český investor navíc podstupuje měnové riziko CHF vůči koruně.

Ask the AI about Roche Holding AG All signals